Clinical Trial Update: Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating whether dabrafenib changes the pharmacokinetics of rosuvastatin and midazolam after a single dose; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CRESTOR (Rosuvastatin)
• TAFINLAR (DABRAFENIB)
• Versed (Midazolam)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED